Celldex Therapeutics (CLDX) Assets Average (2011 - 2026)

Celldex Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $547.1 million for Q1 2026.

• On a quarterly basis, Assets Average fell 28.57% year-over-year to $547.1 million in Q1 2026; TTM through Mar 2026 was $547.1 million, a 28.57% decrease from a year earlier, with the FY2025 full-year figure at $687.7 million, up 9.33% from the prior year.
• Assets Average eased to $547.1 million in Q1 2026 per CLDX's latest filing, from $615.7 million in the prior quarter.
• Across five years, Assets Average topped out at $857.2 million in Q2 2024 and bottomed at $289.8 million in Q3 2023.
• The 5-year median for Assets Average is $547.1 million (2026), against an average of $552.3 million.
• Across the five-year window, Assets Average jumped 187.93% in 2024 and slipped 28.57% in 2026, its largest moves.
• Year by year, Assets Average stood at $361.0 million in 2022, then grew by 3.31% to $372.9 million in 2023, then jumped by 116.59% to $807.8 million in 2024, then slipped by 23.78% to $615.7 million in 2025, then dropped by 11.14% to $547.1 million in 2026.
• Per Business Quant, the three latest CLDX Assets Average figures stand at $547.1 million (Q1 2026), $615.7 million (Q4 2025), and $670.4 million (Q3 2025).